TLR4 and myeloid sarcoma: In vivo functional outcomes supported by behavioral and histological metrics.Dual mechanism: immunomodulation (via TLR4 antagonism in oligodendrocyte progenitor cell OPC) + remyelination; partial insight of downstream signaling mechanism;systemic Ap with known PK;strong translational outlook (advanced safety data in humans and efficacy in multiple MS models).